DE69434844D1 - Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung - Google Patents

Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Info

Publication number
DE69434844D1
DE69434844D1 DE69434844T DE69434844T DE69434844D1 DE 69434844 D1 DE69434844 D1 DE 69434844D1 DE 69434844 T DE69434844 T DE 69434844T DE 69434844 T DE69434844 T DE 69434844T DE 69434844 D1 DE69434844 D1 DE 69434844D1
Authority
DE
Germany
Prior art keywords
disease
proteins
directed
alzheim
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434844T
Other languages
English (en)
Other versions
DE69434844T2 (de
Inventor
La Monte Suzanne M De
Jack R Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE69434844D1 publication Critical patent/DE69434844D1/de
Publication of DE69434844T2 publication Critical patent/DE69434844T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
DE69434844T 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung Expired - Fee Related DE69434844T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20
US50559 1993-04-20
PCT/US1994/004321 WO1994023756A1 (en) 1993-04-20 1994-04-20 Neural thread protein gene expression and detection of alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69434844D1 true DE69434844D1 (de) 2006-10-19
DE69434844T2 DE69434844T2 (de) 2006-12-14

Family

ID=21965952

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435136T Expired - Fee Related DE69435136D1 (de) 1993-04-20 1994-04-20 Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung
DE69434844T Expired - Fee Related DE69434844T2 (de) 1993-04-20 1994-04-20 Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69435136T Expired - Fee Related DE69435136D1 (de) 1993-04-20 1994-04-20 Geneexpression der Neurofilamentproteine und Nachweis der alzheimeschen Erkrankung

Country Status (11)

Country Link
EP (2) EP0697893B1 (de)
JP (2) JP3513859B2 (de)
KR (1) KR100392244B1 (de)
AT (2) ATE406444T1 (de)
CA (1) CA2161097A1 (de)
DE (2) DE69435136D1 (de)
DK (2) DK0697893T3 (de)
ES (2) ES2255054T3 (de)
NZ (1) NZ266072A (de)
PT (1) PT1564293E (de)
WO (1) WO1994023756A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AU1110297A (en) * 1995-12-12 1997-07-03 Kyowa Hakko Kogyo Co. Ltd. Novel dnas, novel polypeptides and novel antibodies
EP0975651A4 (de) 1997-02-26 2005-03-09 Gen Hospital Corp Transgene tiere und zellinien zur erkennung von zur behandlung oder vorbeugung der alzheimerschen krankheit wirksamen medikamente
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
EP1006794B1 (de) 1997-03-12 2007-11-28 Robert W. Esmond Verfahren zur behandlung oder prävention der alzheimerischen krankheit
EP1541166B1 (de) * 2001-05-16 2007-12-19 Nymox Corporation Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen
EP1392347B1 (de) * 2001-05-16 2005-08-03 Nymox Corporation Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
EP1714979A3 (de) * 2001-11-16 2007-04-25 Nymox Corporation Peptide für die Behandlung von Tumoren und anderen Zuständen, die das entfernen oder zerstören von Zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DK1994152T3 (da) 2006-02-28 2013-03-11 Nymox Corp Peptider der er effektive i behandlingen af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2023217890A1 (en) * 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3309972B2 (ja) * 1988-12-21 2002-07-29 ザ・ジェネラル・ホスピタル・コーポレイション 神経系疾患または機能障害の検出法

Also Published As

Publication number Publication date
EP0697893A4 (de) 1996-12-18
CA2161097A1 (en) 1994-10-27
DE69434844T2 (de) 2006-12-14
NZ266072A (en) 1997-07-27
JP2004097227A (ja) 2004-04-02
JPH08509808A (ja) 1996-10-15
DK0697893T3 (da) 2006-02-20
ES2255054T3 (es) 2006-06-16
AU6666994A (en) 1994-11-08
PT1564293E (pt) 2008-12-02
ATE406444T1 (de) 2008-09-15
EP1564293B9 (de) 2009-08-19
AU674581B2 (en) 1997-01-02
WO1994023756A1 (en) 1994-10-27
KR100392244B1 (ko) 2003-11-28
ATE312348T1 (de) 2005-12-15
EP0697893A1 (de) 1996-02-28
EP1564293A1 (de) 2005-08-17
EP1564293B1 (de) 2008-08-27
JP3513859B2 (ja) 2004-03-31
ES2312913T3 (es) 2009-03-01
DK1564293T3 (da) 2009-01-12
DE69435136D1 (de) 2008-10-09
EP0697893B1 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
DE69434844D1 (de) Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung
EP0442961A4 (en) Hybrid procoagulant proteins
SE8106641L (sv) Hybrida humanleukocytinterferoner
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
ATE231551T1 (de) Huntingtin-dna, protein und verwendung
DK0939804T4 (da) Neutrokin-alpha
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
ATE73494T1 (de) Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose.
ATE301716T1 (de) Vmp-ähnliche sequenzen von pathogener borrelia
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69635207D1 (de) Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist.
FI863188A0 (fi) Kombinationsfoerfaranden foer producering av serinproteas-inhibitorer och foer dessa anvaendbara dna-sekvenser.
NO177863C (no) Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
BR9915066A (pt) Processo para identificar proteìnas de expressão traduzidas de uma sequência de nucleotìdeos, proteìna recombinante purificada, sequência de nucleotìdeos, processos de triagem para identificar clones de expressão em uma biblioteca, para triagem de uma biblioteca de sequências de nucleotìdeos, para identificar sequências de genes antigênicos de uma amostra de sequências de nucleotìdeos e para identificar uma sequência de gene antigênica terapêutica, vetor recombinante, célula hospedeira, sequência de aminoácidos, polipeptìdeo isolado e purificado, anticorpo, e, processo para tratar uma infecção
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
ATE187202T1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
NO962596L (no) Nytt tumorsupressorgen
ZA200207883B (en) The High Bone Mass Gene of 11Q13.3.
ATE366810T1 (de) Menschliche p51-gene und deren genprodukte
DE69033553D1 (de) Rekombinante herstellung von laktoperoxidase
EP0839910A3 (de) Spo-rel, ein relA/spoT Homolog aus Staphylococcus
ATE198218T1 (de) Htfiiia gen
TH23725A (th) วัคซีนป้องกันโรคบิดสำหรับสัตว์ปีก
TH38577A (th) การทำรหัส dna ของโปรตีนที่กระตุ้นเร่งพลาสมิโนเจน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee